Minerva Neurosciences’ (NERV) Neutral Rating Reiterated at HC Wainwright
HC Wainwright restated their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research note released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $5.00 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com initiated coverage on shares of Minerva Neurosciences in a research note on Saturday, February 22nd. They […]
HC Wainwright restated their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research note released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $5.00 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com initiated coverage on shares of Minerva Neurosciences in a research note on Saturday, February 22nd. They […]
